Unknown

Dataset Information

0

High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.


ABSTRACT: Roughly two-thirds of all breast cancers are ER?-positive and can be treated with the antiestrogen, Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 y. Aberrant DNA methylation, an epigenetic mechanism that alters gene expression in cancer, is thought to play a role in this resistance. To develop an understanding of Tamoxifen-resistance and identify novel pathways and targets of aberrant methylation, DNA from MCF-7 breast cancer cells and Tamoxifen-resistant derivatives, TMX2-11 and TMX2-28, were analyzed using the Illumina HumanMethylation450 BeadChip. Normalizing against MCF-7 values, ER?-positive TMX2-11 had 4000 hypermethylated sites and ER?-negative TMX2-28 had over 33?000. Analysis of CpG sites altered in both TMX2-11 and TMX2-28 revealed that the Tamoxifen-resistant cell lines share 3000 hypermethylated and 200 hypomethylated CpGs. ZNF350 and MAGED1, two genes hypermethylated in both cell lines, were examined in greater detail. Treatment with 5-aza-2?deoxycitidine caused a significant reduction in promoter methylation of both ZNF350 and MAGED1 and a corresponding increase in expression in TMX2-28. A similar relationship between methylation and expression was not detected in TMX2-11. Our findings are indicative of the variable responses to methylation-targeted breast cancer therapy and highlight the need for biomarkers that accurately predict treatment outcome.

SUBMITTER: Williams KE 

PROVIDER: S-EPMC3962540 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.

Williams Kristin E KE   Anderton Douglas L DL   Lee Maxwell P MP   Pentecost Brian T BT   Arcaro Kathleen F KF  

Epigenetics 20131113 2


Roughly two-thirds of all breast cancers are ERα-positive and can be treated with the antiestrogen, Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 y. Aberrant DNA methylation, an epigenetic mechanism that alters gene expression in cancer, is thought to play a role in this resistance. To develop an understanding of Tamoxifen-resistance and identify novel pathways and targets of aberrant methylation, DNA from MCF-7 breast cancer cells and Tamoxifen-resistant  ...[more]

Similar Datasets

| S-ECPF-GEOD-14513 | biostudies-other
| S-ECPF-GEOD-22664 | biostudies-other
| S-EPMC7746845 | biostudies-literature
2009-12-10 | GSE14513 | GEO
| S-EPMC6034260 | biostudies-literature
2009-12-09 | E-GEOD-14513 | biostudies-arrayexpress
2010-12-31 | GSE22664 | GEO